litlas
ログインアカウント作成

Corey J. Langer

1993–2025 年に発表

139
論文数
32,896
被引用数
89
h 指数
135
i10 指数

被引用数

Corey J. Langer の年別被引用数1933 年: 被引用 1 件1996 年: 被引用 4 件1997 年: 被引用 10 件1998 年: 被引用 10 件1999 年: 被引用 11 件2000 年: 被引用 21 件2001 年: 被引用 25 件2002 年: 被引用 47 件2003 年: 被引用 103 件2004 年: 被引用 108 件2005 年: 被引用 165 件2006 年: 被引用 158 件2007 年: 被引用 215 件2008 年: 被引用 197 件2009 年: 被引用 262 件2010 年: 被引用 264 件2011 年: 被引用 280 件2012 年: 被引用 250 件2013 年: 被引用 230 件2014 年: 被引用 217 件2015 年: 被引用 198 件2016 年: 被引用 179 件2017 年: 被引用 251 件2018 年: 被引用 299 件2019 年: 被引用 946 件2020 年: 被引用 1,067 件2021 年: 被引用 998 件2022 年: 被引用 680 件2023 年: 被引用 491 件2024 年: 被引用 759 件2025 年: 被引用 372 件2026 年: 被引用 12 件1934〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,470 件、この内訳の 27.4%中国: 引用元論文 1,596 件、この内訳の 12.6%イタリア: 引用元論文 693 件、この内訳の 5.5%イギリス: 引用元論文 597 件、この内訳の 4.7%日本: 引用元論文 574 件、この内訳の 4.5%カナダ: 引用元論文 543 件、この内訳の 4.3%フランス: 引用元論文 518 件、この内訳の 4.1%ドイツ: 引用元論文 514 件、この内訳の 4%スペイン: 引用元論文 418 件、この内訳の 3.3%オランダ: 引用元論文 371 件、この内訳の 2.9%オーストラリア: 引用元論文 315 件、この内訳の 2.5%韓国: 引用元論文 293 件、この内訳の 2.3%
0%27.4%その他 21.9%

機関

分野

  • Medicine77.8%
  • Biochemistry, Genetics and Molecular Biology14.9%
  • Immunology and Microbiology2.3%
  • Physics and Astronomy1%
  • Engineering0.7%
  • Materials Science0.6%
  • その他2.7%

トピック

  • Lung Cancer Treatments and Mutations11.2%
  • Cancer Immunotherapy and Biomarkers8.2%
  • Lung Cancer Research Studies7%
  • Lung Cancer Diagnosis and Treatment6.1%
  • Cancer Genomics and Diagnostics3%
  • Head and Neck Cancer Studies2.1%
  • その他62.4%

共著者

全論文

検索で開く
  1. Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients

    著者: Divij Mathew, Melina E. Marmarelis, Caitlin Foley, Joshua Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana Davis, Maximillian Diehn, Josephine R. Giles, Alexander C. Huang, Wei‐Ting Hwang, Nancy R. Zhang, Adam J. Schoenfeld, Erica L. Carpenter, Corey J. Langer, E. John Wherry, Andy J. Minn - Science 2024 被引用: 207

  2. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    著者: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 被引用: 1,392

  3. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

    著者: Charu Aggarwal, Jeffrey C. Thompson, Taylor A. Black, Sharyn I. Katz, Ryan Fan, Stephanie S. Yee, Austin L. Chien, Tracey L. Evans, Joshua Bauml, Evan Alley, Christine Ciunci, Abigail T. Berman, Roger B. Cohen, David Lieberman, Krishna S. Majmundar, Samantha L. Savitch, Jennifer J.D. Morrissette, Wei‐Ting Hwang, Kojo S.J. Elenitoba‐Johnson, Corey J. Langer, Erica L. Carpenter - JAMA Oncology 2018 被引用: 490

  4. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

    著者: Walter J. Curran, Rebecca Paulus, Corey J. Langer, R. Komaki, Jong Seok Lee, Stephen L. Hauser, B. Movsas, Todd H. Wasserman, Seth A. Rosenthal, Elizabeth Gore, Mitchell Machtay, William T. Sause, James D. Cox - JNCI Journal of the National Cancer Institute 2011 被引用: 1,235

  5. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

    著者: Joan H. Schiller, David Harrington, Chandra P. Belani, Corey J. Langer, Alan Sandler, James E. Krook, Junming Zhu, David H. Johnson - New England Journal of Medicine 2002 被引用: 4,984

  6. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

    著者: Andy Trotti, A. D. Colevas, A. Setser, Valerie W. Rusch, David P. Jaques, Volker Budach, Corey J. Langer, Brittany L. Murphy, Richard L. Cumberlin, C. Norman Coleman - Seminars in Radiation Oncology 2003 被引用: 2,570

  7. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer

    著者: Lova Sun, Benjamin Aaron Bleiberg, Wei‐Ting Hwang, Melina E. Marmarelis, Corey J. Langer, Aditi P. Singh, Roger B. Cohen, Ronac Mamtani, Charu Aggarwal - JAMA Oncology 2023 被引用: 148

  8. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

    著者: Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromı́r Roubec, Luboš Petruželka, Libor Havel, Sujith Kalmadi, Jeffrey P. Ward, Zoran Andrić, Thierry Berghmans, David E. Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim G.J.V. Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey J. Langer - The Lancet Oncology 2023 被引用: 101

  9. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

    著者: Steven Powell, Delvys Rodríguez‐Abreu, Corey J. Langer, Ali Tafreshi, Luis Paz‐Ares, Hans‐Georg Kopp, Jerónimo Rafael Rodríguez‐Cid, Dariusz M. Kowalski, Ying Cheng, Takayasu Kurata, Mark M. Awad, J. Lin, Bin Zhao, M. Catherine Pietanza, Bilal Piperdi, Marina Chiara Garassino - Journal of Thoracic Oncology 2021 被引用: 183

  10. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

    著者: Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, Panli Cardona, Emily Chan, Tracy Varrieur, Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong - Nature Medicine 2024 被引用: 89

  11. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

    著者: Luis Paz‐Ares, Alexander I. Spira, David Raben, David Planchard, Byoung Chul Cho, Mustafa Özgüroğlu, Davey B. Daniel, Augusto Villegas, David Vicente, Rina Hui, S. Murakami, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, A-M. Boothman, Helen Broadhurst, Catherine Wadsworth, P. Dennis, Scott Antonia, Corinne Faivre‐Finn - Annals of Oncology 2020 被引用: 224

  12. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy

    著者: Jeffrey C. Thompson, Erica L. Carpenter, Benjamin A. Silva, J Rosenstein, Austin L. Chien, Katie Quinn, Carin R. Espenschied, Allysia J. Mak, Lesli A. Kiedrowski, Martina I. Lefterova, Rebecca J. Nagy, Sharyn I. Katz, Stephanie S. Yee, Taylor A. Black, Aditi P. Singh, Christine Ciunci, Joshua Bauml, Roger B. Cohen, Corey J. Langer, Charu Aggarwal - JCO Precision Oncology 2021 被引用: 105

  13. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    著者: Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn, Karen L. Reckamp, Karin Holmskov Hansen, Sang‐We Kim, Rudolf M. Huber, Howard West, Harry J.M. Groen, Maximilian J. Hochmair, Natasha B. Leighl, Scott Gettinger, Corey J. Langer, Luis G. Paz-Ares Rodríguez, Egbert F. Smit, Edward S. Kim, William M. Reichmann, Frank G. Haluska, David Kerstein, D. Ross Camidge - Journal of Clinical Oncology 2017 被引用: 583

  14. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

    著者: Stephen Bagley, Shawn Kothari, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey L. Evans, John A. Kosteva, Christine Ciunci, Peter Gabriel, Jeffrey C. Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby‐Sandy, Faith Mutale, Gloria A DiLullo, Roger B. Cohen, Anil Vachani, Corey J. Langer - Lung Cancer 2017 被引用: 529

  15. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer

    著者: Joshua Bauml, Rosemarie Mick, Christine Ciunci, Charu Aggarwal, Christiana Davis, Tracey L. Evans, Charuhas Deshpande, Linda Miller, Pooja Patel, Evan Alley, Christina Knepley, Faith Mutale, Roger B. Cohen, Corey J. Langer - JAMA Oncology 2019 被引用: 320

  16. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    著者: Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather A. Wakelee, Nick Thatcher - Journal of Thoracic Oncology 2017 被引用: 243

  17. Clinicopathologic Features of Advanced Squamous NSCLC

    著者: Mark A. Socinski, Coleman K. Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather A. Wakelee, Carlos Mayo, Nick Thatcher - Journal of Thoracic Oncology 2016 被引用: 197

  18. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

    著者: Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih‐Hsin Yang, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Mehmet Altan, Shadia I. Jalal, Amit Panwalkar, Matthew A. Gubens, Lecia V. Sequist, Sanatan Saraf, Bin Zhao, Bilal Piperdi, Corey J. Langer - Journal of Thoracic Oncology 2020 被引用: 183

  19. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer

    著者: Salma K. Jabbour, Abigail T. Berman, Roy H. Decker, Yong Lin, Steven J. Feigenberg, Scott Gettinger, Charu Aggarwal, Corey J. Langer, Charles B. Simone, Jeffrey D. Bradley, Joseph Aisner, Jyoti Malhotra - JAMA Oncology 2020 被引用: 123

  20. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma

    著者: Jeffrey C. Thompson, Christiana Davis, Charuhas Deshpande, Wei‐Ting Hwang, Seth Jeffries, Alexander C. Huang, Tara C. Mitchell, Corey J. Langer, Steven Μ. Albelda - Journal for ImmunoTherapy of Cancer 2020 被引用: 114

  21. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

    著者: Charu Aggarwal, Melina E. Marmarelis, Wei‐Ting Hwang, Dylan Scholes, Tara McWilliams, Aditi P. Singh, Lova Sun, John A. Kosteva, Michael R. Costello, Roger B. Cohen, Corey J. Langer, Abigail Doucette, Peter Gabriel, Lawrence N. Shulman, Katharine A. Rendle, Jeffrey C. Thompson, Justin E. Bekelman, Erica L. Carpenter - JCO Precision Oncology 2023 被引用: 44

  22. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

    著者: Rudolf M. Huber, Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, Howard West, Karen L. Reckamp, Natasha B. Leighl, Marcello Tiseo, Egbert F. Smit, Dong‐Wan Kim, Scott Gettinger, Maximilian J. Hochmair, Sang-We Kim, Corey J. Langer, Myung‐Ju Ahn, Edward S. Kim, David Kerstein, Harry J.M. Groen, D. Ross Camidge - Journal of Thoracic Oncology 2019 被引用: 144

  23. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy

    著者: Jeffrey C. Thompson, Wei‐Ting Hwang, Christiana Davis, Charuhas Deshpande, Seth Jeffries, Yashoda Rajpurohit, Vinod Krishna, Denis Smirnov, Raluca Verona, Matthew V. Lorenzi, Corey J. Langer, Steven Μ. Albelda - Lung Cancer 2019 被引用: 142

  24. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

    著者: Hossein Borghaei, Corey J. Langer, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Baerin Houghton, Takayasu Kurata, Ying Cheng, Jianxin Lin, M. Catherine Pietanza, Bilal Piperdi, Shirish M. Gadgeel - Cancer 2020 被引用: 111